Join

Compare · CNCR vs RICE

CNCR vs RICE

Side-by-side comparison of Loncar Cancer Immunotherapy ETF (CNCR) and Rice Acquisition Corp. (RICE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CNCR and RICE operate in n/a (n/a), so they compete in similar markets.
  • RICE carries a market cap of $536.2M.
  • RICE has more recent analyst coverage (1 ratings vs 0 for CNCR).
MetricCNCRRICE
Company
Loncar Cancer Immunotherapy ETF
Rice Acquisition Corp.
Price
$9.16+2.35%
$18.23+0.52%
Market cap
-
$536.2M
1M return
-
-
1Y return
-
-
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NASDAQ
NYSE
IPO
n/a
2020
News (4w)
0
0
Recent ratings
0
1
CNCR

Loncar Cancer Immunotherapy ETF

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

RICE

Rice Acquisition Corp.

Rice Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Carnegie, Pennsylvania.

Latest CNCR

No recent items for Loncar Cancer Immunotherapy ETF.

Latest RICE